Through a partnership between CarryGenes Therapeutics and Cellular Accommodations Inc, CarryGenes Holding Kb was created. The purpose of CG Holding Kb has been to support the development of a human synthetic chromosome (the “hSynC”) that resides inside a patient’s cell which serves as the next generation cell therapy treatment of under-addressed and unaddressed human genetic diseases. CarryGenes Holding Kb’s wholly owned subsidiary, CG Bioengineering is focused on the advancement of this hSynC – Cell Engineering Product program. We invite you to link to CG Bioengineering (www.cgbioengineering.com) for further information.
